UNSPSC 51382702: Sulindac

This classification denotes a cyclooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 184SNS8VUH. European Medicines Agency schedules Sulindac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10744MIG. Sulindac generally arises in the molecular formula C20H17FO3S.

UNSPSC 51382702 Sulindac is a Commodity code representing individual pharmaceutical products, but recent state and local solicitations tagged under this code do not align with sulindac procurement specifically. Instead, the opportunities reflect broader pharmaceutical supply contracting—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products. The mismatch suggests either a tagging error in the source data or that sulindac itself sees minimal recent procurement activity at the state and local level. Issuing bodies in the recent record include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple jurisdictions including Minnesota and Oregon). The work being solicited ranges from emergency-response pharmaceuticals and safe drug handling systems to bulk generic pharmaceutical supply agreements for government health programs and employee benefit plans.

Recent opportunities show geographic activity in Florida, Texas, and Minnesota/Oregon through cooperative purchasing. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, requiring quarterly deliveries to the Seminole County Community Health Building with all shipping costs included in bids and a two-year initial term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for establishing direct contracts with self-insured health plans outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026, and evaluation weighted heavily toward price competitiveness (75 percent).